FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38816360.
- Also identified by DOI 10.1038/s41467-024-48397-9 and PMC identifier 11139667.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Nasopharyngeal carcinoma (NPC)-mediated immunosuppression within the tumor microenvironment (TME) frequently culminates in the failure of otherwise promising immunotherapies. In this study, we identify tumor-intrinsic FLI1 as a critical mediator in impairing T cell anti-tumor immunity. A mechanistic inquiry reveals that FLI1 orchestrates the expression of CBP and STAT1, facilitating chromatin accessibility and transcriptional activation of IDO1 in response to T cell-released IFN-γ. This regulatory cascade ultimately leads to augmented IDO1 expression, resulting in heightened synthesis of kynurenine (Kyn) in tumor cells. This, in turn, fosters CD8<sup>+</sup> T cell exhaustion and regulatory T cell (Treg) differentiation. Intriguingly, we find that pharmacological inhibition of FLI1 effectively obstructs the CBP/STAT1-IDO1-Kyn axis, thereby invigorating both spontaneous and checkpoint therapy-induced immune responses, culminating in enhanced tumor eradication. In conclusion, our findings delineate FLI1-mediated Kyn metabolism as an immune evasion mechanism in NPC, furnishing valuable insights into potential therapeutic interventions.
Medical subject headings
- Kynurenine
- Interferon-gamma
- Proto-Oncogene Protein c-fli-1
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Tumor Microenvironment
- T-Lymphocytes, Regulatory
- STAT1 Transcription Factor